Azitra, Inc. (AZTR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Francisco D. Salva | President, CEO & Director | 427.03k | -- | 1971 |
| Mr. Travis M. Whitfill M.P.H., Ph.D. | Co-Founder, COO & Director | 161.61k | -- | 1990 |
| Mr. Norman Staskey | CFO, Treasurer & Secretary | 314.02k | -- | 1970 |
Azitra, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 10
Description
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
February 9, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission